Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,429 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150.
Finn RS, Galle PR, Ducreux M, Cheng AL, Reilly N, Nicholas A, Hernandez S, Ma N, Merle P, Salem R, Li D, Breder V. Finn RS, et al. Among authors: hernandez s. Liver Cancer. 2024 Jun 21;13(6):655-668. doi: 10.1159/000539897. eCollection 2024 Dec. Liver Cancer. 2024. PMID: 39687036 Free PMC article.
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Finn RS, et al. Among authors: hernandez s. N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745. N Engl J Med. 2020. PMID: 32402160 Clinical Trial.
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR, Finn RS, Qin S, Ikeda M, Zhu AX, Kim TY, Kudo M, Breder V, Merle P, Kaseb A, Li D, Mulla S, Verret W, Xu DZ, Hernandez S, Ding B, Liu J, Huang C, Lim HY, Cheng AL, Ducreux M. Galle PR, et al. Among authors: hernandez s. Lancet Oncol. 2021 Jul;22(7):991-1001. doi: 10.1016/S1470-2045(21)00151-0. Epub 2021 May 27. Lancet Oncol. 2021. PMID: 34051880 Clinical Trial.
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab.
Shen YC, Liu TH, Nicholas A, Soyama A, Yuan CT, Chen TC, Eguchi S, Yoshizumi T, Itoh S, Nakamura N, Kosaka H, Kaibori M, Ishii T, Hatano E, Ogawa C, Naganuma A, Kakizaki S, Cheng CH, Lin PT, Su YY, Chuang CH, Lu LC, Wu CJ, Wang HW, Rau KM, Hsu CH, Lin SM, Huang YH, Hernandez S, Finn RS, Kudo M, Cheng AL. Shen YC, et al. Among authors: hernandez s. J Clin Oncol. 2024 Dec;42(34):4060-4070. doi: 10.1200/JCO.24.00645. Epub 2024 Aug 28. J Clin Oncol. 2024. PMID: 39197119 Free PMC article.
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study.
Qin S, Ren Z, Feng YH, Yau T, Wang B, Zhao H, Bai Y, Gu S, Li L, Hernandez S, Xu DZ, Mulla S, Wang Y, Shao H, Cheng AL. Qin S, et al. Among authors: hernandez s. Liver Cancer. 2021 Jul;10(4):296-308. doi: 10.1159/000513486. Epub 2021 Apr 23. Liver Cancer. 2021. PMID: 34414118 Free PMC article.
Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database.
Kaplan DE, Tan R, Xiang C, Mu F, Hernandez S, Ogale S, Li J, Lin Y, Shi L, Singal AG. Kaplan DE, et al. Among authors: hernandez s. Cancers (Basel). 2024 Oct 17;16(20):3508. doi: 10.3390/cancers16203508. Cancers (Basel). 2024. PMID: 39456602 Free PMC article.
1,429 results